Image: Wikimedia Commons (U.S. Air Force photo by Tech. Sgt. Jocelyn A. Ford) The Food and Drug Administration (FDA) has denied a review to the pharmaceutical giant Moderna over its latest experimental flu vaccine. The FDA’s chief vaccine official, Dr. Vinay Prasad, declined to sign off on Moderna’s submission after raising objections to how the study was conducted. Regulators took issue with the company’s decision to benchmark its new vaccine against the less effective Fluarix Quadrivalent. Prasad, who serves as director of the Center for Biologics Evaluation and Research (CBER), said that the Moderna trial was not sufficiently “adequate and well-controlled” because comparing it with standard flu shots “does not reflect the best-available standard of care.” In a press release on Tuesday, Moderna’s CEO Stéphane…
Click here to read the full article at The Gateway Pundit.
